Gary Pigeau received his Ph.D. in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined Cytiva, formerly part of GE Healthcare’s Life Sciences business, and the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in 2016. He serves as Director of the collaborative facility in Toronto, Ontario with focus on biology support for New Product Introductions, internal technology development projects and contract process development services in cell and gene therapy.
Recent Posts
- Genetically engineering a treatment for incurable brain tumors
- Stem Cells for Species Conservation – ISSCR Webinar celebrating Earth Day 2024
- Micro-patterning-a new system to induce alveolar and airway epithelial cells
- Clinical Trial for Parkinson’s Disease – First-in-Human Phase 1/2a Autologous Neuronal Cell Replacement Therapy
- Accelerated aging may be a cause of increased cancers in people under 55
- New Zealand cancer trial: CAR T-cell therapy for lymphoma, leukaemia and myeloma is saving lives